Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
<< anterior 21 a 40 de 633 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Anónimo. Hepatitis C in the USA and Europe: two problems, one solution. Lancet 2013;381:1688. [Ref.ID 95443]
22. Cita con resumen
Xueref S, Daviaud J, Pal S. The Global Fund and pharmacovigilance systems in resourcelimited settings. Lancet 2013;381:1360. [Ref.ID 95279]
23. Cita con resumen
Saunders P, Kamal-Yanni M. Action to preserve WHO's core medicines-related roles—1 year on. Lancet 2013;381:293-4. [Ref.ID 94814]
24. Cita con resumen
Klein HG. Should blood be an essential medicine?. N Engl J Med 2013;368:199-201. [Ref.ID 94785]
25.
Tanne JH. How the search for new drugs for neglected diseases is paying off. BMJ 2012;344:18-9. [Ref.ID 92679]
26. Cita con resumen
Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012;379:413-31. [Ref.ID 92308]
27. Cita con resumen
Moszynski P. Global Fund suspends support for all new projects until 2014. BMJ 2011;343:1124. [Ref.ID 91914]
28. Cita con resumen
Limb M. Study reveals corporate links of global foundations. BMJ 2011;342:891. [Ref.ID 90478]
29. Cita con resumen
Sridhar D, Gostin LO. Reforming the World Health Organization. JAMA 2011;305:1585-6. [Ref.ID 90414]
30. Cita con resumen
McGirk J. Norway investigates Gaza's drug crisis. Lancet 2011;377:1225-6. [Ref.ID 90367]
31. Cita con resumen
Zarocostas J. NIH puts first antiretroviral patent into worldwide drug pool. BMJ 2010;341:751. [Ref.ID 89523]
32.Tiene citas relacionadas Cita con resumen
Pasqualone F. Bristol-Myers Squibb clarification on didanosine supply. Lancet 2010;376:1054. [Ref.ID 89424]
33. Cita con resumen
Shetty P. Bernard Pécoul: championing the cause of neglected diseases. Lancet 2010;376:677. [Ref.ID 89245]
34.
Santosham M, Chandran A, Fitzwater S, Fischer-Walker C, Baqui AH, Black R. Progress in barriers for the control of diarrhoeal disease. Lancet 2010;376:63-7. [Ref.ID 88858]
35.Tiene citas relacionadas Cita con resumen
Kamal-Yanni M, Nichols K, Tallah E, Otwoma N. Open letter to Lamberto Andreotti, Chief Executive Officer Bristol-Myer Squibb. Lancet 2010;375:2213. [Ref.ID 88825]
36.Tiene citas relacionadas Cita con resumen
Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SSS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, and the Pyronaridine-artesunate Study Team. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010;375:1457-67. [Ref.ID 88419]
37.Tiene citas relacionadas
Nosten FH. Pyronaridine-artesunate for uncomplicated falciparum malaria. Lancet 2010;375:1413-4. [Ref.ID 88412]
38.Tiene citas relacionadas Cita con resumen
Anónimo. Malaria 2010: more ambition and accountability please. Lancet 2010;375:1407. [Ref.ID 88409]
39. Cita con resumen
Wise J. GSK makes details of potential antimalarials freely available. BMJ 2010;340:234. [Ref.ID 87779]
40.Tiene citas relacionadas Cita con resumen
't Hoen E. Pharmaceutical companies and the UNITAID patent pool. Lancet 2010;375:30. [Ref.ID 87530]
Seleccionar todas
 
<< anterior 21 a 40 de 633 siguiente >>